LifeSci Partnering focuses on securing non-dilutive capital and assets for clients
through buy-side and sell-side strategic partnering transactions.

Deal Types & Track Record

  • Out-licensing
  • In-licensing
  • R&D Collaborations
  • Product Acquisitions & Divestitures
  • Mergers & Acquisitions
0
transactions
0 Billion USD+
deal value
0+
contacts worldwide

Robust Business Development Support

Robust Business
Development Support

Transaction Advisory

  • Enhance existing BD capabilities
  • Expand existing target list (if needed)
  • Initiate a formal partnering process to generate deal tension and maximize value
  • Structure deal based on substantial LifeSci transaction experience (e.g., value share split, upfront/milestone/royalty allocations)
  • Support deal negotiations, particularly financial terms

Select Highlighted Deals

2021

Exclusive China License

Deal Terms Undisclosed

2021

Various Collaborations

Deal Terms Undisclosed

2019

Global Exclusive Option to License

Undisclosed ($3 Million Upfront)

2019

Ex-US & Japan Exclusive License

$568 Million

2019

Global Exclusive Option to License

$481 Million

2018

Structured Buy-Out

$1.04 Billion

See All Transactions ›